Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
JANX Quote, Financials, Valuation and Earnings
Last price:
$14.31
Seasonality move
:
51.13%
Day range:
$13.82 - $14.16
52-week range:
$13.76 - $61.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
85.62x
P/B ratio:
0.87x
Volume:
1.4M
Avg. volume:
2.5M
1-year change:
-75.12%
Market cap:
$849.3M
Revenue:
$10.6M
EPS (TTM):
-$1.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$3.1M | -$0.61 | 599.64% | -80.26% | $65.12 |
|
EDIT
Editas Medicine, Inc.
|
$4.9M | -$0.38 | -72.38% | -61.06% | $5.13 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.42% | -80.04% | $87.99 |
|
MNKD
MannKind Corp.
|
$80.2M | $0.03 | 30.4% | 17.65% | $9.61 |
|
STOK
Stoke Therapeutics, Inc.
|
$6.2M | -$0.57 | -77.5% | -289.69% | $34.25 |
|
VERA
Vera Therapeutics, Inc.
|
-- | -$1.13 | -- | -76.12% | $75.15 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$14.12 | $65.12 | $849.3M | -- | $0.00 | 0% | 85.62x |
|
EDIT
Editas Medicine, Inc.
|
$2.19 | $5.13 | $213.8M | -- | $0.00 | 0% | 4.02x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$80.33 | $87.99 | $13B | -- | $0.00 | 0% | 13.68x |
|
MNKD
MannKind Corp.
|
$5.93 | $9.61 | $1.8B | 62.95x | $0.00 | 0% | 5.83x |
|
STOK
Stoke Therapeutics, Inc.
|
$31.86 | $34.25 | $1.8B | 48.28x | $0.00 | 0% | 9.04x |
|
VERA
Vera Therapeutics, Inc.
|
$53.91 | $75.15 | $3.4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
2.27% | -0.738 | 1.54% | 35.54x |
|
EDIT
Editas Medicine, Inc.
|
85.41% | 3.856 | 24.32% | 2.81x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
MNKD
MannKind Corp.
|
124.56% | 0.023 | 13.7% | 2.54x |
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.663 | 0.37% | 6.17x |
|
VERA
Vera Therapeutics, Inc.
|
16.22% | 2.262 | 4.16% | 11.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$9.5M | -$35.3M | -10.68% | -10.94% | -352.51% | -$12.9M |
|
EDIT
Editas Medicine, Inc.
|
$6.8M | -$24.5M | -149.99% | -246.73% | -325.44% | -$31.3M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
|
VERA
Vera Therapeutics, Inc.
|
-$564K | -$83.9M | -48.69% | -55.53% | -- | -$62M |
Janux Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns JANX or EDIT?
Editas Medicine, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -332.98%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Editas Medicine, Inc.'s return on equity of -246.73%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M EDITEditas Medicine, Inc.90.44% -$0.28 $92.2M -
What do Analysts Say About JANX or EDIT?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 361.17%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 134.02%. Given that Janux Therapeutics, Inc. has higher upside potential than Editas Medicine, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Editas Medicine, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 EDITEditas Medicine, Inc.6 7 0 -
Is JANX or EDIT More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.441, suggesting its more volatile than the S&P 500 by 144.07%.
-
Which is a Better Dividend Stock JANX or EDIT?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or EDIT?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are larger than Editas Medicine, Inc. quarterly revenues of $7.5M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 85.62x versus 4.02x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.85.62x -- $10M -$24.3M EDITEditas Medicine, Inc.4.02x -- $7.5M -$25.1M
-
Which has Higher Returns JANX or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -82.06%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About JANX or IONS?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 361.17%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 9.54%. Given that Janux Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is JANX or IONS More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock JANX or IONS?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or IONS?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 85.62x versus 13.68x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.85.62x -- $10M -$24.3M IONSIonis Pharmaceuticals, Inc.13.68x -- $156.7M -$128.6M
-
Which has Higher Returns JANX or MNKD?
MannKind Corp. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 9.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About JANX or MNKD?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 361.17%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.08%. Given that Janux Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Janux Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 MNKDMannKind Corp.8 0 0 -
Is JANX or MNKD More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.
-
Which is a Better Dividend Stock JANX or MNKD?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or MNKD?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than MannKind Corp.'s net income of $8M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 62.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 85.62x versus 5.83x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.85.62x -- $10M -$24.3M MNKDMannKind Corp.5.83x 62.95x $82.1M $8M
-
Which has Higher Returns JANX or STOK?
Stoke Therapeutics, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -360.68%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M -
What do Analysts Say About JANX or STOK?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 361.17%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $34.25 which suggests that it could grow by 7.5%. Given that Janux Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 STOKStoke Therapeutics, Inc.9 0 0 -
Is JANX or STOK More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.
-
Which is a Better Dividend Stock JANX or STOK?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or STOK?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 48.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 85.62x versus 9.04x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.85.62x -- $10M -$24.3M STOKStoke Therapeutics, Inc.9.04x 48.28x $10.6M -$38.3M
-
Which has Higher Returns JANX or VERA?
Vera Therapeutics, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of --. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Vera Therapeutics, Inc.'s return on equity of -55.53%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M VERAVera Therapeutics, Inc.-- -$1.26 $476.1M -
What do Analysts Say About JANX or VERA?
Janux Therapeutics, Inc. has a consensus price target of $65.12, signalling upside risk potential of 361.17%. On the other hand Vera Therapeutics, Inc. has an analysts' consensus of $75.15 which suggests that it could grow by 39.41%. Given that Janux Therapeutics, Inc. has higher upside potential than Vera Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Vera Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.15 1 0 VERAVera Therapeutics, Inc.10 2 0 -
Is JANX or VERA More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vera Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JANX or VERA?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vera Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Vera Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or VERA?
Janux Therapeutics, Inc. quarterly revenues are $10M, which are larger than Vera Therapeutics, Inc. quarterly revenues of --. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Vera Therapeutics, Inc.'s net income of -$80.3M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Vera Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 85.62x versus -- for Vera Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.85.62x -- $10M -$24.3M VERAVera Therapeutics, Inc.-- -- -- -$80.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
